Apr 15 2010
PositiveID Corporation is presently developing an in vivo glucose-sensing RFID microchip. This microchip is now in the Phase II development stage.
This stage focuses on the optimization of this glucose sensing system in terms of its glucose response during the presence of interstitial fluid matrix components and blood. Once the Phase II development stage is completed successfully, the company plans to integrate the microchip’s electronic interface and the glucose sensor. The Phase II development stage is likely to be completed during mid-2010.
PositiveID has recently fulfilled its first order to supply 7,500, RFID microchips of 8-mm size to a customer. These microchips were made by Raytheon Microelectronics España that operates as ELCAN Optical Technologies. These microchips are likely to be utilized for animal health, medical device identification, and medical diagnostic applications.
PositiveID’s CEO and Chairman, Scott R. Silverman, expects that the production and delivery of the initial batch 8-mm microchips will help his company to further develop the microchip for enabling detection and treatment of medical conditions in animals and humans, besides identification applications.
Source: http://www.PositiveIDCorp.com